Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, MRI and negative 14-3-3 immunoblot by Šarac, Helena et al.
  
 
    
 
Središnja medicinska knjižnica 
 
 
 
 
 
 
Šarac, H., Hajnšek, S., Bašić, S., Henigsberg, N., Radoš, M., Šimić, G. (2008) 
Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy 
proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, 
MRI and negative 14-3-3 immunoblot. Collegium Antropologicum, 32 (Suppl. 1). 
pp. 199-204. 
 
 
 
 
 
http://medlib.mef.hr/372 
 
 
 
 
 
 
 
 
 
 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
 
  
Magnetic Resonance Spectroscopy and 
Measurement of Tau Epitopes of Autopsy Proven Sporadic Creutzfeldt-Jakob Disease in 
a Patient with Non-Specific Initial EEG, MRI and Negative 14-3-3 Immunoblot 
 
Helena Šarac1, Sanja Hajnšek2, Silvio Bašić2, Neven Henigsberg1, Marko Radoš1 and 
Goran Šimić1 
 
1Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb and 
Diagnostic Center »Neuron«, Zagreb, Croatia 
2Department of Neurology, University Hospital Centre »Zagreb« and School of Medicine, 
University of Zagreb, Zagreb, Croatia 
 
ABSTRACT 
 
Limited potential of electroencephalogram (EEG), magnetic resonance images (MRI) and 
cerebrospinal fluid (CSF) test for 14-3-3 protein in the clinical diagnosis of sporadic 
Creutzfeldt-Jakob disease (sCJD) resulted in developments in diagnostic premortem 
tehniques. Recent studies provided evidence that magnetic resonance spectroscopy (MRS) 
and measurement of total- tau (T-tau) and phospho-tau (P-tau) may be useful to identify 
patients with CJD. We combined detected metabolic changes in the brain by MRS and 
measured T-tau and tau-pT181 by ELISA, and tau-pT231 by Western blot in a patient with 
autopsy proven sCJD. Our results show that in contrast to negative CSF 14-3-3 protein, 
nonspecific EEG and MRI, MRS revealed metabolic alterations in regions of the brain that 
has appeared normal on MRI, and tau tests has shown measurable levels of phosphorylated 
and non-phosphorylated isoforms in CSF. We conclude that rapidly progressive dementia 
with negative 14-3-3 test and non-specific initial EEG and MRI must still be considered in 
the differential diagnosis of the sCJD. Combination of serial functional MRI along with MRS 
study and measurement of tau ratio could improve the early diagnosis of sCJD. The current 
case is the first attempt to study results of the use of MRS and tau tests in a case of sCJD with 
diagnostic dilemma. 
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Introduction 
 
Although the diagnosis of the sporadic Creutzfeldt-Jakob disease (sCJD) is primarily based 
upon the evolution of clinical symptoms such as dementia, ataxia and myoclonus, many 
diagnostic techniques including electroencephalogram (EEG), magnetic resonance imaging 
(MRI) and cerebrospinal fluid (CSF) 14-3-3 test are accepted in the premortem diagnostic 
criteria1,2. Due to limited potential of these methods, some authors recently have concluded 
that diagnostic criteria for CJD may need revision and reliable diagnostic methods are 
required3. Magnetic resonance spectroscopy (MRS) selectively indicates neuronal destruction 
and the cell type most severely affected in sCJD and has already been included in the 
investigation of suspected CJD4. Although neuronal damage in sCJD may corresponds with 
other dementia disorders, including new variant CJD (vCJD), Alzheimer’s disease (AD) and 
human immunodeficiency virus (HIV), specific metabolic alteration may be seen in sCJD 
using MRS5. Raised concentrations of tau protein (T-tau) and hyperphosphorylated tau (P-tau) 
in CSF may be found in sCJD as well as in a variety of neurodegenerative processes. 
Concentration of CSF T-tau is several magnitudes higher in CJD than other dementia because 
of massive neuronal destruction6. In conditions associated with neurofibrillary tangles (NFT) 
or tau inclusions such as AD and FTD, but not in CJD, tau proteins get hyperphosphorylated3 
and increased CSF concentration of P-tau may be found7. Riemenschneider et colleagues8 
showed that simultaneous measurement of T-tau and P-tau by ELISA and calculation of P-
tau/T-tau ratio discriminate CJD from other dementia processes completely. Zetterberg and 
colleagues3 reported usefulness of the opposite ratio calculation, and showed that T-tau/P-tau 
ratio were much higher in CJD, than in other dementia disorders. In a recent study, Goodall et 
colleagues9 showed that T-tau/P-tau ratio may be of diagnostic value in distinguishing 
between sCJD and vCJD but does not improve the diagnostic accuracy of tau protein alone in 
the diagnosis of sCJD9. We reported results of the MRS and tau tests including ELISA and 
Western blot immunoassay in a patient with autopsy proven sCJD. 
 
 
Case Report 
 
A 63-year-old woman, member of the negative history family, has been admitted in October 
2005 to the Neurology Department due to memory loss, walking disturbances, visual loss, and 
speech difficulty, rapidly deteriorating over two months. Neurological examination revealed 
dementia (Mini Mental State Examination was 5), ataxia, akinetic mutism, visual loss and 
sensory hypersensitivity. Mental and neurological status deteriorated rapidly with a fatal 
outcome ten days after admission. Blood processing has shown elevated concentrations 
of the neuron specific enolase (NSE 20.74 µg/L) and normal level of S-100 protein. Sample of 
CSF was aquired via lumbar puncture at 9 AM according to the routine protocol and collected 
in polypropylene tubes in 1 mL aliquot. Aliquot was centrifuged at 4 °C at 10,000 g for 10 
minutes and stored at –80°C untily analysis. Analysis of the CSF has shown elevated glucose 
4.00 mmol/L, proteins 0.87 g/L, high level of NSE 160 µg/L, S-100 protein 11.2 µg/L and 
negative 14-3-3 protein. By using monoclonal antibodies specific for aminoacid threonin 
phosphorylated at 231 site, Western blot immunoassay was performed. Monoclonal antibody 
was generous gift from Peter Davies (Albert Einstein College of Medicine, Bronx, NY). 
Western blot immunoassay showed us a presence of relatively large amount of tau-
phosphorylated at threonine231 (tau-pT231) protein in CSF sample. On the resulting 
membrane our protein is represented by strong black band at the height of approximately 70 
kDa. The other bands visible on the membrane represent non-specific bindings (Figure 1). 
Simultaneously, mean concentration of CSF T-tau and tau phosphorylated at threonine-181 
(tau-pT181) were measured using enzyme-like immunosorbent assay (ELISA), (Biosource 
Invitrogen kits). We measured concentration of both total tau protein and tau-pT181 
according to the manufacturer’s instructions. Extremely high concentration of total-tau was 
detected (12,100 pg/mL vs 234±92 pg/mL) and relatively low concentration of tau 
phosphorylated at threonine-181 (<20 pg/mL vs 54±33 pg/mL).We also included calculation 
of T-tau/ptau-pT181 ratio and tau-pT181/T-tau ratio in the CSF investigation. The tau-
pT181/T-tau protein ratio was 0.0016 in our case and was significantly lower than cut-off for 
AD>0.33. The first EEG examination has shown non-specific slow activity 3 Hz diffusely 
along with periodic spike and wave complexes (PSWC) (Figure 2). Subsequent, preterminal 
EEG has shown one-per second three phases spike and wave pattern, which is specific for 
sCJD (Figure 3). Structural and functional imaging results were not consistent with the 
diagnosis of sCJD in the presented case. Initial and subsequent MRI scans showed diffuse 
high signal intensity over white matter without Gd-enhancement on T1 MRI, that was 
misconceived to demyelinisation lesions of the vascular type of dementia. The last MRI scan 
verified just slightly increased T2 and FLAIR MRI signal in caudate nuclei and putamen 
along with diffuse, cortico-subcortically distributed high signal of white matter (Figure 4). 
The subarachnoidal space was mildly enlarged without significant cortical atrophy 
characteristic for any dementia disorder. Magnetic resonance spectroscopy (MRS) has been 
measured in basal ganglia, parietal white matter and grey matter in frontal, occipital and 
cerebella locations. The MRS in the striatum exhibited moderate reduction in N-
acetylaspartate (NAA) indicating loss of neuronal vitality, decreased NAA relative to 
creatines (Cr) up to 50% and slightly increased level of myoinositol (mI) up to 25% 
(Figure 5). The similar metabolite changes have been found in the insular cortex. The spectra 
of hippocampus showed severe reduction in NAA/Cr ratio up to 60%, decreased Cho/Cr ratio 
20%, while the level of mI was within the normal range (Figure 6). The metabolite pattern in 
occipital grey matter and white matter showed low decrease in NAA up to 20%. (Figure 7). 
At autopsy, neuropathology and immunohistochemistry analysis confirmed sCJD. 
Spongiform changes and gliosis were seen microscopically throughout the gray matter, 
dominantly in the left temporal lobe. Immunohistochemical verification by using the antibody 
12F10 has shown an immunoreactivity pattern suggestive of CJD with widespread 
pathological prion protein (PrP) deposits in both cerebral and cerebella cortices in a diffuse 
synaptic pattern. There are no changes suggestive of variant CJD PrP-fluoride plaques, neither 
unicentric nor multicentric. Sequencing of the prion protein gene (PRNP) to exclude 
mutations and characterize the polymorphism at codon 129 has not been made without 
informed consent of relatives. 
 
 
Discussion 
 
Difficulties in establishing the clinical diagnosis of the sCJD, especially early in the course of 
the disease require application of the expanded set of diagnostic techniques. In the recent 
years detection of MRS10 metabolic alterations of the brain and tau tests11 take place in the 
clinical investigation of sCJD. Here, we reported the diagnostic accuracy of the measurement 
of tau epitopes and MRS of sCJD in a patient with unspecific EEG, MRI and negative CSF 
14-3-3 protein. We combined Western blot immunoassay by using monoclonal antibodies 
specific for tau-pT231 and measurement CSF concentrations of T-tau and tau-pT181 using 
ELISA. Calculation of T-tau/tau-p181 ratio and taupT181/T-tau ratio were also performed to 
discriminate sCJD from vCJD and other dementia. Western blot immunoassay showed us a 
presence of large amount of CSF tau-phosphorylated at threonine 231 (tau-pS231) in CSF. 
Tau-phosphorylated at threonine 231 detected by using antibody specific for aminoacid 
threonin phosphorylated at 231 site and is represented by strong black band at the height of 
approximately 70 kDa suggesting that the diagnosis of AD was highly likely, but not sCJD. 
Furthemore, we measured significantly raised concentration of CSF T-tau (12.100 pg/mL, 
normal value is 215 pg/mL±75) by using ELISA (Biosource Invitrogen kits). On the other 
hand, concentration of tau-phosphorylated at threonine 181 was slightly raised and was less 
than 20 pg/mL. To reach the best result for distinguishing CJD from other diagnoses, we used 
cut-off values for T-tau in sCJD12 (>1300 pg/mL) and cut-off values for tau-pT181 in sCJD9 
(>50 pg/mL), and combined tests for T-tau, T-tau/tau-pT181 ratio and tau-pT181/T-tau (<60) 
ratio that were previously described9. Riemenschneider et al. previously demonstrated that 
calculation of P-tau/T-tau ratio in CSF may be a useful maker to discriminate CJD from other 
neurodegenerative diseases8. Calculation of tau-pT181/T-tau was 0.0017 and is several times 
smaller than cut-off for AD diagnosis (>0.33)13. Calculation of T-tau/tau-pT181 ratio was 
605. It is much higher than cut-off value for CJD, and discriminates this case of sCJD from 
other non-CJD dementia disorders. Comparing to previous studies tau-pT181/T-tau separated 
this patient from other dementia including AD with a high sureness9. Lower concentrations of 
tau-pT181 may reflect a lower extent of phosphorylation at the threonine 181 and suggests 
that neurofibrillary tangles (NFT) are low or absent in sCJD14 in opposite to the AD. 
Other CSF biomarkers NSE and S-100 protein were extremely high several and were several 
magnitudes higher than in cut-off for other dementia. However, these markers show less 
sensitivity and specificity.EEG, MRI and CSF 14-3-3 test result were not consistent with the 
diagnoses in sCJD patients. Initial EEG examination showed diffuse slow waves bilaterally. 
Subsequent EEG has shown non-specific periodical sharp wave complexes (PSWC). This 
pattern may be seen seen early in the disease course in about 75% cases of sCJD15, but it 
could also be seen in metabolic encephalopathies, hereditary leukoarayosis, infectious 
encephalitis. Only preterminal EEG has shown one-per second sharp wave pattern, typical 
EEG changes that occurs most often in patients with sCJD and have average sensitivity and 
specificity of 92%15 in comparison to vCJD. However, this case confirms that EEG has 
limitied diagnostic potential in sCJD because specific EEG pattern does not appear until the 
last phase of the disease. The view that CSF 14-3-3 protein represents reliable marker of 
extensive brain destruction and is highly sensitive and specific in sCJD and vCJD16–20 has 
recently been challenged. Geschwind et al. recently found that only 17 of 32 patients with 
autopsy-proven CJD had a positive result for the 14-3-3 test21. False negative results in 
autopsy-proven, sCJD, and false positive results in other neurological disorders including AD, 
FTD, viral encephalitis, amyotrophic lateral sclerosis, multiple sclerosis, stroke, vascular 
dementia, paraneoplastic syndromes17 limit the potential of this marker. Negative 14-3-3 
test in this case does not exclude the diagnosis of CJD as only one CSF 14-3-3 protein test 
was performed at later stage of the disease. Positive CSF 14-3-3 protein could be found in 
almost all cases of sCJD within one year from first symptoms of disease, but it could be 
negative after one year from the onset12,22,25,26. Structural and functional imaging results were 
not consistent with the diagnosis in this patient. MRI showed diffuse high signal intensity of 
white matter, without characteristic signal change within basal ganglia or thalami, cortical 
atrophy, occipital cortical high signal intensity, high signal intensity over white matter20,23–25. 
Previous studies showed that initial MRI scans shows signal change within basal ganglia in 
high proportion of sCJD patients (70%), and subsequent MRI scans usually demonstrate low 
signal intensity of basal ganglia, increased T2 signals within the white matter and diffuse 
cortical atrophy20,23–25. Cortico-subcortical hyperintensities over white matter usually develop 
in the later stage of the disease, and are linked with slow clinical course and longer duration 
of illness25. Serial MR scans in our case may be foolproof of these findings. In contrast to 
MRI findings, MRS showed results consistent with the diagnosis of sCJD. We have found a 
significant reduction in NAA/Cr ratio in regions of the brain that appeared normal on MRI 
(lack of T2/FLAIR/DWI signal changes). Decreased NAA represents a robust but nonspecific 
marker for neuronal loss or dysfunction26,27. In previous studied cases, NAA/Cr ratio was 
normal in spite of the obvious FLAIR/DWI changes, that might indicate spongiform changes 
of still viable cells28. Studies showed that these metabolic changes occur early in the natural 
history of CJD, and may not be found during the period of incubation or before disease onset. 
However, MRS metabolic changes occur earlier than MRI changes. Decreased NAA 
(neuronal-axonal marker) up to 50% was detected in all measured voxels, increased mI/Cr 
ratios were found in basal ganglia (striatum) and insular cortex, along with normal level of Cr, 
and slightly reduced Cho/cr ratio for 10–20%. Increased level of mI occurs early in the history 
of CJD and AD, but not in other dementia and healthy subjects. While NAA/Cr ratio is more 
or less reduced in all measured voxels in CJD, decreased NAA/Cre ratio may be found only in 
hippocampus in early stage of AD and additionally in primary cortex in the later stages of the 
AD. The increased mI/Cr ratios were calculated in basal ganglia (caudate nucleus and 
putamen) and insular cortex. The most prominent increased level of mI may be found in AD 
(hippocampus and cerebral cortex), in vCJD (pulvinar thalami) as well as in herpes simplex 
encephalitis, neuro-cysticercosis and occasionally in progressive multifocal 
leucoencephalopathy. The severe reduction in NAA/Cr ratio in all measured voxels and 
increased level of mI exclusively in striatum show promise as an early biomarker for sCJD. 
At autopsy, immunohistochemistry using the antibody 12F10 has shown an immunoreactivity 
pattern suggestive of sCJD. There were no PrP-plaques suggestive of variant CJD (vCJD). 
Verification of the PrP by Western blot immunoassay is the most reliable diagnostic marker 
for all forms of CJD29. Sequencing of the prion protein gene (PRNP) has not been made due 
to a lack of informed consent of relatives. By using appropriate immunohistochemical 
techniques, false-positive results are not found. 
 
 
Conclusion 
 
The case presented suggests that patients with rapidly progressive dementia, ataxia and 
myoclonus, along with non-specific MRI, EEG and negative CSF 14-3-3 protein, must still be 
considered in the differential diagnosis of sCJD. Serial fMRI, MRS and combined tau tests 
may represent powerful diagnostic methods for CJD in a patients with unspecific diagnostic 
criteria. Detection of the decreased NAA/Cr ratio in all regions of the brain along with 
increased level of mI within the striatum may discriminate between sCJD and other dementia 
disorders including vCJD with a high sureness. Using monoclonal antibodies specific for tau-
pT231, Western blot immunoassay detects but does not precisely measured concentration of 
tau-pT231 in CSF. Only the quantification of tau epitopes may improve detection and 
differential diagnosis of dementia disorders. Present case supports recent study that using of 
monoclonal antibodies, measurement of T-tau and tau-pT181 by ELISA and calculation of 
tau-pT181/T-tau and T-tau/tau-pT181 ratios may discriminate sCJD from other dementia. At 
the same time, these tests do not improve the diagnostic accuracy of tau protein alone in 
distinguishing between sCJD and vCJD. Proton spectroscopy showed specific metabolic 
alterations in the areas of the brain affected by neuronal destructionand could be of diagnostic 
value in distinguishing between sCJD and vCJD, as well as other dementia disorders. 
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Legends 
 
 
Fig. 1.Western blot immunoassay shows strong black band at the height of approximately 70 
kDa representing large amount of phospho-tau231 protein detected by antibody specific for 
aminoacid threonin phosphorylated at 231 site. 
 
 
 
 
Fig. 2. Initial EEG examination shows non-specific slow activity 3 Hz diffusely and periodic 
spike and wave complexes (PSWC). EEG – electroencephalogram. 
 
 
 
Fig. 3. Preterminal EEG (7 days after initial EEG) shows one per second three phase spike 
and wave pattern, the most specific for sCJD. (sCJD – sporadic Creutzfeld-Jakob disease). 
 
 
 
 
Fig. 4. Axial T2WI and FLAIRWI MRI show increased signal intensity in caudate nuclei and 
more prominent, diffusely distributed, cortico-subcortical hyperintensities of white matter. 
(MRI – magnetic resonance imaging). 
 
 
 
 
 
Fig. 5. MR spectroscopy in all examined regions of the brain shows reduced NAA/Cr ratio up 
to 40%. Levels of Cho and mI were within the normal range. (MRS-magnetic resonance 
spectroscopy, NAA – N – acetylaspartate, Cr – creatine, Cho – choline, mI – myo-inositol) 
 
 
 
Fig. 6. MRS of the hippocampus showed reduced NAA/Cr and Cho/Cr ratio, and normal mI 
level. 
 
 
 
Fig. 7. MRS of the occipital grey matter showed solely less prominent 
decrease in NAA. 
 
 
SPEKTROSKOPIJA MAGNETSKOM REZONANCIJOM I MJERENJE TAU 
EPITOPA U DIJAGNOSTICI SPORADIČNOG OBLIKA CREUTZFELDT-
JAKOBOVE BOLESTI U PACIJENTICE S NESPECIFIČNIM 
EGG, MRI I NEGATIVNIM 14-3-3 TESTOM U CEREBROSPINALNOM LIKVORU 
 
 
SAŽETAK 
 
Ograničene mogućnosti elektroencefalografije (EEG), magnetske rezonancije (MRI) i testa na 
14-3-3 protein u cerebrospinalnom likvoru (CSL) utjecale su na razvitak novih dijagnostičkih 
metoda u dijagnostici sporadičnog oblika Creutzfeldt-Jakobove bolesti (sCJB) premortalno. 
Novije studije pokazale su da spektroskopija magnetskom rezonancijom (MRS) i mjerenje 
koncentracije tau epitopa mogu u CSL koristiti u identificiranju oboljelih of sCJB. Mi smo 
simultano određivali metaboličke promjene mozga koristeći MRS i mjerili koncentracije 
ukupnog i fosforiliranog tau proteina (tau-pT181) u CSL koristeći ELISA metodu, te 
odre|ivali prisutnost tau-pT231proteina metodom Western blot u CSL pacijentice sa 
obdukcijom dokazanom sCJB. Naši rezultati pokazuju da usprkos negativnom nalazu 14-3-3 
proteina u CSL, nespecifičnim promjenama na inicijalnom EEG-u i MRI, protonska 
spektroskopija je otkrila specifične metaboličke promjene i u regijama mozga koje su se 
doimale normalnim na MRI, a tau testovi su pokazali povišene vrijednosti nefosforiliranog i 
fosforiliranog tau proteina u CSL. Zaključujemo da kod brzo progresivne demencije sa 
negativnim 14-3-3 testom u CSL, uz nespecifične EEG i MRI promjene, ne treba isključiti 
sCJB. Kombinacija serijskog funkcionalnog MRI (fMRI), protonske spektroskopije i MRS uz 
mjerenje koncentracije nefosforiliranog i ukupnog tau proteina u CSL može unaprijediti 
dijagnostiku sCJB. Prema našim spoznajama, ova studija po prvi put opisuje istovremenu 
primjenu MRS tehnike i tau testova u identifikaciji dijagnostički dvojbenog oblika sCJB. 
 
